Skip to main content

$3.3M to Fund Trial of Ai-Designed Bacteriophage Therapy for HAP/VAP

-

 

$3.3M to Fund Trial of Ai-Designed Bacteriophage Therapy for HAP/VAP

$3.3M to Fund Trial of Ai-Designed Bacteriophage Therapy for HAP/VAP

Locus Biosciences will conduct a clinical trial for its Ai-designed bacteriophage therapeutic for HAP/VAP caused by antibiotic-resistant P. aeruginosa.


RT’s Three Key Takeaways:

  1. Federal support for phage therapy – Locus Biosciences received a $3.3 million NIAID contract, with potential expansion to $28 million, to advance a Phase 1b clinical trial of its engineered bacteriophage LBP-PA01 for antibiotic-resistant Pseudomonas aeruginosa pneumonia.
  2. AI-designed precision antibacterial – LBP-PA01 was developed using Locus’s AI- and robotics-driven platform, which rapidly designs and optimizes engineered bacteriophage cocktails to selectively kill drug-resistant bacteria.
  3. Addressing a critical public health threat – The program targets hospital-acquired and ventilator-associated pneumonia, major ICU killers for which antibiotic-resistant P. aeruginosa is a CDC-designated serious threat with limited effective treatment options.


Locus Biosciences was awarded a $3.3 million contract by the National Institute of Allergy and Infectious Diseases (NIAID) to support a proof-of-concept clinical trial of LBP-PA01, an AI-designed bacteriophage therapeutic for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by antibiotic-resistant Pseudomonas aeruginosa bacteria.

The company says the contract could with further funding of up to a total of $28 million available over the course of the contract if all project milestones are met. The awarded contract will

Under contract No. 75N93025C00035, NIAID will fund a Phase 1b clinical trial of LBP-PA01, enabling Locus to evaluate safety, efficacy, and optimal dosing in patients with P. aeruginosa infections that have become increasingly difficult to treat using conventional antibiotics.

Locus created LBP-PA01 using its AI-driven discovery engine, where robotics and machine learning converge to rapidly design next-generation engineered bacteriophage therapies. This platform experimentally measures millions of phage-bacteria interactions and uses these outcomes to simulate over a quadrillion (one million billion) potential phage combinations in silico, identifying the most effective therapeutic cocktail candidates. Within this framework, multimodal large language models trained on genomic and functional datasets predict optimal genomic engineering configurations for incorporating antibacterial payloads, enabling precise synthetic biology optimization of phage genomes to enhance the killing of target pathogens. By integrating automation and AI, the Locus platform compresses what once took years of trial-and-error into weeks of systematic testing, enabling a rapid response to emerging drug-resistant pathogens.

“Partnering with HHS to advance multiple programs under NIAID and BARDA is an exciting evolution for Locus as we deploy our platform to deliver precision antibacterial therapies across diverse indications and routes of administration,” said Paul Garofolo, CEO of Locus Biosciences. “With NIAID driving innovation targeting respiratory infections and BARDA advancing solutions for urinary tract infections, we are united under a shared mission to solve the global antimicrobial resistance crisis. This collaboration underscores the power of Locus’s AI-enabled drug development platform and its advanced U.S.-based manufacturing to accelerate a new generation of engineered bacteriophage therapeutics.”

Hospital-acquired pneumonia (HAP) is among the most serious and common healthcare-associated infections, accounting for approximately 15–20% of hospital-onset infections and remains a leading cause of mortality in intensive care units. P. aeruginosa is a frequent cause of HAP and ventilator-associated pneumonia (VAP), responsible for up to 24% of ICU respiratory infections in some studies. The U.S. Centers for Disease Control and Prevention (CDC) has identified antibiotic-resistant P. aeruginosa as a serious public health threat, underscoring the urgent need for precision therapies to combat this pathogen.


Article taken from, copyright belongs to : https://respiratory-therapy.com/disorders-diseases/infectious-diseases/other-infections/ai-designed-bacteriophage-hap-vap/

Comments

Post a Comment

Popular posts from this blog

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more